Trial Profile
An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Subjects With Fabry Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Migalastat (Primary) ; Agalsidase alfa; Agalsidase beta
- Indications Fabry's disease
- Focus Pharmacokinetics
- Sponsors Amicus Therapeutics
- 27 Aug 2014 New source identified and integrated (European Clinical Trials Database record: EudraCT2010-022709-16)
- 02 Apr 2014 New trial record